Copaxone Sales Data
| Rank 10 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Copaxone U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 10 | $851,351 | -4.69% | 202 | -5.16% |
| Q3 2013 | 10 ( 1) |
$893,267 | -4.29% | 213 | -6.58% |
| Q2 2013 | 9 | $933,319 | 0.79% | 228 | -0.44% |
| Q1 2013 | 9 | $926,021 | 1.98% | 229 | -8.03% |
| Q4 2012 | 9 | $908,061 | 3.47% | 249 | 0.81% |
| Q3 2012 | 9 ( 4) |
$877,591 | 9.93% | 247 | 9.78% |
| Q2 2012 | 13 (3) |
$798,336 | 6.65% | 225 | 6.13% |
| Q1 2012 | 16 | $748,585 | 4.59% | 212 | -7.42% |
| Q4 2011 | 16 (1) |
$715,745 | 0.98% | 229 | 0.88% |
| Q3 2011 | 17 (2) |
$708,803 | -1.66% | 227 | -0.44% |
| Q2 2011 | 19 (3) |
$720,747 | 0.29% | 228 | n/a |
| Q1 2011 | 16 | $718,635 | n/a | 228 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
